Glycylpressin

Glycylpressin is a prescription medication whose active ingredient is terlipressin acetate, a synthetic vasopressin analog. It is supplied for intravenous administration; specific strength and dosage form are not disclosed in this summary. The drug acts as a V1 vasopressin receptor agonist, producing vasoconstriction and raising systemic vascular resistance. Glycylpressin is marketed in the European Union and is classified as a hemodynamic agent used in specialized clinical settings.

Glycylpressin is indicated for specific acute conditions that involve severe bleeding or renal dysfunction related to liver disease.

- Management of acute variceal bleeding in patients with portal hypertension. - Treatment of hepatorenal syndrome type 1 in cirrhotic patients. - Adjunctive therapy to control hemorrhage during endoscopic procedures for esophageal varices. - Supportive use in selected cases of refractory hypotension where vasoconstriction is required. - Temporary stabilization of hemodynamics in patients undergoing liver transplantation when severe vasodilation is present. - Off‑label consideration for septic shock unresponsive to conventional vasopressors, under specialist supervision.

The safety profile of Glycylpressin reflects its vasoconstrictive activity; side effects are reported across a range of frequencies, from mild and transient to potentially life‑threatening. Patients receiving the drug are monitored for cardiovascular and renal responses.

Common: - Headache - Nausea or vomiting - Abdominal discomfort or cramps - Flushing or warmth at the infusion site - Dizziness or light‑headedness - Transient tachycardia

Serious: - Severe hypertension or hypertensive crisis - Cardiac arrhythmias, including atrial or ventricular ectopy - Ischemic complications such as myocardial infarction, limb ischemia, or bowel infarction - Acute renal failure or worsening of existing renal impairment - Pulmonary edema - Severe electrolyte disturbances (e.g., hyponatremia)

When prescribing Glycylpressin, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse events.

- Known hypersensitivity to terlipressin, vasopressin analogs, or any excipients. - Uncontrolled hypertension or severe cardiovascular disease. - Active coronary artery disease or recent myocardial infarction. - Severe peripheral vascular disease or risk of limb ischemia. - Pregnancy and lactation status unknown; use only if potential benefit justifies risk. - Concomitant use of other potent vasoconstrictors. - Impaired renal function requiring dose adjustment or close monitoring.

Glycylpressin may interact with other agents that affect vascular tone, cardiac rhythm, or renal function; awareness of these interactions helps minimize complications.

Avoid: - Other vasopressors or sympathomimetic agents (e.g., norepinephrine, phenylephrine) due to additive vasoconstriction. - Monoamine oxidase inhibitors combined with certain serotonergic drugs that could increase risk of hypertension. - Concomitant use with potent vasodilators (e.g., nitroglycerin) that may counteract therapeutic effect.

Use with caution: - Beta‑blockers, which may mask tachycardia. - Diuretics, especially loop diuretics, that can exacerbate electrolyte imbalances. - Anticoagulants or antiplatelet agents, as severe hypertension may increase bleeding risk.